About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

We got an oldfashioned bidding war going on between Nova Nordisk and Fizer to take control of Metsera. Our viewers may remember it was last week or actually a few weeks ago Fizer had a deal to acquire this company to try to build its presence uh in the GLP1 arena essentially uh reducing obviously people's uh weight um where it really has not had a great deal of success going up against the incumbents Eli Liy and Nova Nordis. But then Novo came in last week with an interesting offer in terms of its structure ...

Key Takeaways Pfizer's Q3 adjusted EPS of $0.87 beat estimates but fell 18% year over year.Revenues dropped 6% to $16.7B, hurt by lower Comirnaty and Paxlovid sales.Pfizer reaffirmed revenue outlook and lifted 2025 EPS guidance to $3.00-$3.15.Pfizer (PFE) reported third-quarter 2025 adjusted earnings per share of 87 cents, which comprehensively beat the Zacks Consensus Estimate of 66 cents per share. Earnings declined 18% year over year.Adjusted EPS includes an acquired in-process R&D charge of 20 cents per ...

U.S. equity markets are experiencing a midday retreat on Tuesday, November 4, 2025, with major indexes pulling back as investors digest a mix of corporate earnings, upcoming economic data, and a cautious sentiment surrounding the technology sector. The initial optimism seen at the start of the week has waned, with profit-taking evident in several high-flying tech stocks.Midday Market Momentum and Index PerformanceAs midday trading progresses, Wall Street is broadly lower, primarily driven by declines in the ...

Core Viewpoint - Pfizer Inc. is a leading biopharmaceutical company with a strong reputation due to its diverse product portfolio and strategic collaborations, particularly in the development of treatments for various diseases and the COVID-19 vaccine [1][2]. Financial Performance - Pfizer's consensus price target has increased from $29.20 to $31 over the past year, indicating a positive outlook from analysts [2][6]. - Analyst Louise Chen from Cantor Fitzgerald has set a high price target of $75, reflecting strong expectations for the stock [2][6]. - The company has adjusted its earnings per share (EPS) guidance upwards for 2025, signaling robust financial performance and boosting investor confidence [3][6]. Challenges and Resilience - Despite facing challenges such as declining demand for coronavirus products and approaching patent expirations, Pfizer remains a resilient stock to watch [4][6]. - The company's ability to navigate these hurdles while maintaining a positive outlook from analysts highlights its resilience [4][6]. Market Context - Broader economic factors, including the Supreme Court's review of tariffs and upcoming employment data from ADP, could influence market conditions, which are crucial for investors considering Pfizer's growth potential [5].

TESLA WATCH: Elon Musk Pay Deal In Focus Novo Nordisk (NVO) said it would pay up to $10 billion to acquire obesity-focused Metsera (MTSR), topping Pfizer's (PFE) recently hiked $8.1 billion proposal. The news sent Metsera stock flying more than 15% to 70. Meanwhile, Pfizer stock rose a fraction, while Novo shares gained 1.2%. Pfizer and Metsera have been locked in a heated battle over the last week to buy Metsera. Pfizer's first bid, in September, was for $4.9 billion. Last week, Novo Nordisk made an unsoli ...

A Delaware judge said on Tuesday she did not see in a preliminary evaluation the need to involve the court in the bidding war for Metsera between Pfizer and Novo Nordisk, but did schedule another hearing for 3:15 pm ET on Wednesday to review the process. ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Pfizer (NYSE:PFE) Q3 2025 Earnings Call November 04, 2025 10:00 AM ET Company ParticipantsAkash Tewari - Global Head of Biopharmaceutical ResearchChris Schott - Managing DirectorMohit Bansal - Managing Director and Co-Head of Therapeutics ResearchAlex Hammond - Director and Head of TherapeuticsFrancesca DeMartino - SVP and Chief Investor Relations OfficerAamir Malik - Chief U.S. Commercial Officer and EVPDave Risinger - Senior Managing DirectorVamil Divan - Managing DirectorGeoff Meacham - Managing Director ...

Pfizer (NYSE:PFE) Q3 2025 Earnings Call November 04, 2025 10:00 AM ET Company ParticipantsAkash Tewari - Global Head of Biopharmaceutical ResearchChris Schott - Managing DirectorMohit Bansal - Managing Director and Co-Head of Therapeutics ResearchAlex Hammond - Director and Head of TherapeuticsFrancesca DeMartino - SVP and Chief Investor Relations OfficerAamir Malik - Chief U.S. Commercial Officer and EVPDave Risinger - Senior Managing DirectorVamil Divan - Managing DirectorGeoff Meacham - Managing Director ...